Uveitis: who works on it

One card per institution. Pick a target or a country to narrow the list.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

No running funded project names this disease yet.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants

  NCT07218770· Regeneron Pharmaceuticals· Updated 17 Aug 2026

  “Unfavorable benefit-risk assessment”Registry text, quoted unchanged. Source

• Terminated

  Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes

  NCT03586284· University of California, San Francisco· Updated 5 Mar 2026

  “Funding discontinued.”Registry text, quoted unchanged. Source

• Withdrawn

  Ozurdex Monotherapy Trial

  NCT05101928· Ottawa Hospital Research Institute· Updated 12 Mar 2025

  “The study was withdrawn due to insufficient participant enrollment.”Registry text, quoted unchanged. Source

• Terminated

  Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis

  NCT05384249· ACELYRIN Inc.· Updated 21 Feb 2025

  “Study primary and secondary endpoints did not achieve statistical significance.”Registry text, quoted unchanged. Source

• Terminated

  POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU

  NCT05953688· Alumis Inc· Updated 28 Aug 2024

  “Terminated based on interim efficacy data that did not meet the Sponsor's criteria.”Registry text, quoted unchanged. Source

• Withdrawn

  Intravitreal Sirolimus as Therapeutic Approach to Uveitis

  NCT01280669· Stanford University· Updated 26 Oct 2023

  “Never started due to sponsor decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019)

  NCT07861074· Merck Sharp & Dohme LLC· Source

• A Study of Uveitis in Children <18 Years of Age

  NCT07518134· Jaeb Center for Health Research· Source

• A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants

  NCT07218770· Regeneron Pharmaceuticals· Source

• Pathogen Detection in Infectious Uveitis

  NCT04521673· Xinhua Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Metagenomics for Ocular Inflammation

  NCT06974162· Moorfields Eye Hospital NHS Foundation Trust· Source

• A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

  NCT04088409· Eli Lilly and Company· Source

• Vamikibart in Participants With Uveitic Macular Edema

  NCT05642325· Hoffmann-La Roche· Source

• Birdshot Chorioretinopathy : Prospective Follow-up and Immunogenetic Studies(CO-BIRD)

  NCT05153057· Assistance Publique - Hôpitaux de Paris· Source

• Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine Profiles

  NCT07262437· University of Milan· Source

• A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema

  NCT05642312· Hoffmann-La Roche· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

See which targets of this disease your abstract mentions, and go to the people working on them.